WhatsApp
backNews Article

Sai Parenterals to Acquire Majority Stake in Bion Therapeutics India Through SP Analytics Subsidiary by November 30, 2026

Acquisition funded via IPO proceeds and debt to broaden Sai Parenterals’ pharmaceutical portfolio with Bion becoming a step-down subsidiary

Sai Parenterals Limited, via its wholly owned subsidiary SP Analytics Private Limited, will acquire a majority stake in Hyderabad-based Bion Therapeutics India Private Limited in an all-cash transaction expected to complete by November 30, 2026. The acquisition supports expansion into branded formulations prescription business with Bion becoming a step-down subsidiary.

1 day ago|SAIPARENT+1.05%
Sai Parenterals Limited544742SAIPARENTAcquisition / Amalgamation / Merger / Demerger

Sai Parenterals Limited

Acquisition / Amalgamation / Merger / Demerger

Sai Parenterals Limited announced that its wholly owned subsidiary, SP Analytics Private Limited, will acquire a majority stake in Hyderabad-based Bion Therapeutics India Private Limited in an all-cash transaction expected to close by November 30, 2026.

The Board of Sai Parenterals approved the signing of the acquisition agreement, making Bion Therapeutics a step-down subsidiary upon completion.

The deal will be funded by a combination of proceeds earmarked for General Corporate Purposes from the Company's IPO and additional debt, subject to legal approvals.

Bion Therapeutics operates in the pharmaceutical sector focusing on branded formulations prescription business and reported a turnover of Rs. 28.22 crore for the half-year ended September 30, 2026.

The acquisition is being conducted on an arm's-length basis following independent valuation and complies with relevant regulatory and related party transaction provisions.

Bion Therapeutics was incorporated in 2005 and has shown consistent income with Rs. 47.29 crore reported in FY 2025-26.

Highlights

  • Acquisition to be completed on or before November 30, 2026.
  • Transaction is an all-cash deal funded through IPO proceeds and debt.
  • Bion Therapeutics had a turnover of Rs. 28.22 crore in H1 FY 2026-27.
  • Bion will become a step-down subsidiary post acquisition.
  • Acquisition conducted on arm's-length basis with independent valuation.

Key Data Snapshot

Board Meeting Date16th November, 2026
Acquisition TargetBion Therapeutics (India) Private Limited
Target Turnover (H1 ending Sep 30, 2026)Rs. 28.22 crore
Acquisition Completion DeadlineOn or before 30th November, 2026
Funding SourceIPO proceeds and debt
Acquisition ConsiderationAll-cash deal
Target Business SectorPharma Sector
Subsidiary involvedSP Analytics Private Limited (wholly owned subsidiary)

What happened

  • Sai Parenterals Limited’s Board approved acquisition of majority stake in Bion Therapeutics India Private Limited via its wholly owned subsidiary SP Analytics Private Limited.
  • The transaction is an all-cash deal expected to complete on or before November 30, 2026, making Bion a step-down subsidiary of Sai Parenterals.
  • Funding support will come from the Company’s IPO proceeds earmarked for general corporate purposes and debt, pending requisite approvals.

Key details

  • Bion Therapeutics is based in Hyderabad and operates in the branded formulations prescription pharma segment.
  • Turnover reported by Bion was Rs. 28.22 crore for the half-year ended September 30, 2026, with consistent income over the past three fiscal years.
  • The acquisition will be executed on an arm's-length basis following independent valuation.
  • No governmental or regulatory approvals are required for this acquisition.

Transaction details

  • Acquisition involves majority stake and/or controlling interest in Bion Therapeutics India Private Limited.
  • The acquisition price is based on independent valuation; the transaction consideration is cash-only.
  • Bion was incorporated on September 5, 2005, primarily for pharmaceutical testing and formulations business.

Funding and capital details

  • Necessary funding to SP Analytics Private Limited will utilize proceeds from Sai Parenterals Limited’s IPO earmarked for General Corporate Purposes and debt.
  • All financial support and acquisition funding will comply with applicable laws and require necessary approvals.

More News on Acquisition / Amalgamation / Merger / Demerger

View all

Latest corporate announcements and market updates in Acquisition / Amalgamation / Merger / Demerger.

View all news
Sai Parenterals to Acquire Majority Stake in Bion | Stockk News